apollo

Select Address

Search Medicines
  • Login
  1. Home
  2. Hertrust 440 Powder For Solution Combipack Injection 1's

  3. Hertrust 440 Powder For Solution Combipack Injection 1's Substitute

Hertrust 440 Powder For Solution Combipack Injection 1's Substitute

Substitutes safety advice
call Doctor

Verified Ingredients and Effects

Composition:

TRASTUZUMAB-440MG

Uses:

Hertrust 440 Powder For Solution Combipack Injection 1's is used in the treatment of Breast Cancer and Stomach Cancer. The detailed uses of Hertrust 440 Powder For Solution Combipack Injection 1's are as follows:<br/>• HER2-Positive Breast Cancer: Hertrust 440 Powder For Solution Combipack Injection 1's is used in the treatment of breast cancer and used alone or with other agents to slow disease progression.<br/>• HER2-Positive Gastric and Gastroesophageal Junction Cancer: Hertrust 440 Powder For Solution Combipack Injection 1's is used in treatment of HER2-Positive Gastric and Gastroesophageal Junction Cancer or in combination with chemotherapy for advanced or metastatic cases.<br/>

Medicinal Benefits:

Hertrust 440 Powder For Solution Combipack Injection 1's contains Trastuzumab, which is used for treating patients with HER2-positive breast cancer and HER2-positive metastatic gastroesophageal adenocarcinoma. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of programmed cell death.

FAQs

Hertrust 440 Powder For Solution Combipack Injection 1's is used to treat Breast Cancer and Stomach Cancer.

Hertrust 440 Powder For Solution Combipack Injection 1's contains Trastuzumab, which works by inhibiting the excess production of a protein called human epidermal growth factor receptor 2 (HER2) in mammalian cells. This causes inhibition of the cancer cell growth.

Inform your doctor whether you have received any other cancer treatment. Hertrust 440 Powder For Solution Combipack Injection 1's may cause a decrease in left ventricular ejection fraction, cardiomyopathy, hypersensitivity reactions, pulmonary toxicity, and embryo-fetal toxicity during the treatment. Hence, inform your oncologist if you have any cardiovascular conditions, liver/kidney disease, lung problems, are pregnant, are planning to become pregnant, or are breastfeeding before receiving Hertrust 440 Powder For Solution Combipack Injection 1's.

Consult the doctor immediately, if you experience symptoms of an infection, such as a high temperature, chills, or feeling unwell despite a normal temperature. It could be due to a reduced white blood cell count caused by Hertrust 440 Powder For Solution Combipack Injection 1's, increasing your risk of severe infections. Additionally, swollen feet or ankles, stomach pain, or lower back pain may indicate heart problems.

It is recommended to wait at least 6 months after completing Hertrust 440 Powder For Solution Combipack Injection 1's therapy before trying to get pregnant. This is because the medication can remain in the body for some time and may potentially affect pregnancy. However, it is essential to consult the doctor for personalized advice and to ensure that it is safe for you to become pregnant after this treatment.

The duration of treatment with Hertrust 440 Powder For Solution Combipack Injection 1's will depend on an individual treatment plan, which your doctor will determine based on your specific condition. It may vary based on personal medical conditions and how you respond to the therapy. In some cases, the treatment duration may be shorter or longer. Always attend follow-up appointments as instructed by the doctor for effective treatment.

Fasting is not typically required before administering Hertrust 440 Powder For Solution Combipack Injection 1's. However, it is always best to follow the doctor's specific instructions regarding preparations before treatment. If fasting is necessary, your doctor will provide detailed guidance.

Hertrust 440 Powder For Solution Combipack Injection 1's should be administered through subcutaneous (SC) or intravenous (IV) routes by the doctor or nurse. Do not self-administer.

Hertrust 440 Powder For Solution Combipack Injection 1's should not be administered to patients with HER2-negative cancer cells as it is a monoclonal antibody that specifically targets a protein called human epidermal growth factor receptor 2 (HER2), which is present in high amounts on the surface of specific cancer cells.

The doctor may recommend heart investigations while you are taking Hertrust 440 Powder For Solution Combipack Injection 1's as it may potentially affect heart function. It has been associated with heart-related side effects, including a decrease in left ventricular ejection fraction, which could lead to heart failure in some patients. Monitoring heart health helps detect any issues early, ensuring prompt action to manage the risk. Always follow the doctor's recommendations for regular check-ups during treatment.

During treatment with Hertrust 440 Powder For Solution Combipack Injection 1's for advanced-stage disease, cardiac monitoring was conducted every 3 to 8 months for up to 2 years. However, the doctor will adjust the frequency of heart investigations based on your specific condition and response to treatment. It's essential to follow their advice for optimal monitoring and early detection of any heart-related issues.

The side effects of Hertrust 440 Powder For Solution Combipack Injection 1's include abdominal pain, chills, headache, diarrhoea, fatigue, nausea, back pain, bone pain, oedema, insomnia, fever, dizziness, vomiting, cough, rash, and injection site reactions. Consult the doctor if any of these side effects persist or worsen.